Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster
Terry M. Nolan, Georgia Deliyannis, Maryanne Griffith, Sabine Braat, Lilith F. Allen, Jennifer Audsley, Amy W. Chung, Marcin Ciula, Nicholas A. Gherardin, Michelle L. Giles, Tom P. Gordon, Samantha L. Grimley, Lana Horng, David C. Jackson, Jennifer A. Juno, Katherine Kedzierska, Stephen J. Kent, Sharon R. Lewin, Mason Littlejohn, Hayley A. McQuiltenFrancesca L. Mordant, Thi H.O. Nguyen, Vanessa Pac Soo, Briony Price, Damian F.J. Purcell, Pradhipa Ramanathan, Samuel J. Redmond, Steven Rockman, Zheng Ruan, Joseph Sasadeusz, Julie A. Simpson, Kanta Subbarao, Stewart A. Fabb, Thomas J. Payne, Asuka Takanashi, Chee Wah Tan, Joseph Torresi, Jing Jing Wang, Lin-Fa Wang, Hareth Al-Wassiti, Chinn Yi Wong, Sophie Zaloumis, Colin W. Pouton, Dale I. Godfrey
Research output: Contribution to journal › Article › peer-review
9Citations
(Scopus)
66Downloads
(Pure)
Fingerprint
Dive into the research topics of 'Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster'. Together they form a unique fingerprint.